The science of the newly approved prophylactic human papillomavirus (HPV) vaccines is
clear: vaccination of young women prevents genital type-specific infection with HPV 16 and …

The availability of a prophylactic human papillomavirus (HPV) vaccine for the prevention of
cervical cancer and its precursors offers the potential to reduce cervical cancer incidence …

Published data to date indicate that human papillomavirus (HPV) prevention vaccines are
safe and efficacious in reducing HPV persistence and cervical intraepithelial neoplasia …

The rationale behind current worldwide human papilloma virus (HPV) vaccination programs
starts from two basic premises, 1) that HPV vaccines will prevent cervical cancers and save …

Cervical infections by approximately 15 cancer-associated (carcinogenic) human
papillomavirus (HPV) genotypes cause virtually all cervical cancer and its immediate …

Abstract Cervarix® and Gardasil®, 2 human papillomavirus (HPV) vaccines, have been
approved and implemented globally in young adolescent women with the hope of reducing …

Despite great expectations and promising results of clinical trials, we still lack sufficient
evidence of an effective vaccine against cervical cancer. Several strains of human …

Cervical cancer is the second most common cancer among women worldwide, with about
493,000 new cases diagnosed annually. Of 274,000 deaths due to cervical cancer each …

This issue of Sexual Health has reflected on processes, opportunities and challenges that
human papillomavirus (HPV) vaccines have created for the prevention of cervical cancer …

Human papillomavirus (HPV) infections cause high disease burden. Primary prevention by
vaccination is a major breakthrough. HPV vaccines are well tolerated and safe. Vaccines …